The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APTO | -89.33% | -99.94% | -77.65% | -100% |
| S&P | +15.06% | +95.03% | +14.29% | +1,574% |
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
The company reported very encouraging results from an early-stage study.
Dilution is on the way.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.10M | 13.6% |
| Market Cap | $2.22M | -81.4% |
| Market Cap / Employee | $0.17M | 0.0% |
| Employees | 13 | -62.9% |
| Net Income | -$7.04M | 2.9% |
| EBITDA | -$6.82M | 5.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.30M | -84.4% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.96M | 2547.8% |
| Short Term Debt | $0.41M | 2.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -255.43% | -40.7% |
| Return On Invested Capital | 311.03% | -84.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.10M | 0.0% |
| Operating Free Cash Flow | -$6.10M | -7.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.88 | -2.98 | -1.39 | -0.30 | -100.34% |
| Price to Tangible Book Value | -102.59 | -14.45 | -1.39 | -0.30 | -100.01% |
| Enterprise Value to EBITDA | -1.46 | -8.39 | -2.05 | -1.79 | 160.36% |
| Return on Equity | -294.0% | -361.0% | -694.1% | - | |
| Total Debt | $10.72M | $10.64M | $8.98M | $11.38M | 1290.59% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
